Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy.

PURPOSE Inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase (statins) reduce signs of diabetic retinopathy in diabetic patients and animals. Indirect clinical evidence supports the actions of statins in improving cardiovascular function, but the mechanisms of their protective actions in the retina are not understood. Prior studies have implicated oxidative stress and NADPH oxidase-mediated activation of signal transducer and activator of transcription 3 (STAT3) in diabetes-induced increases in expression of vascular endothelial growth factor (VEGF) and intercellular adhesion molecule (ICAM)-1 and breakdown of the blood-retinal barrier (BRB). Because statins are known to be potent antioxidants, the hypothesis for the current study was that the protective effects of statins in preventing diabetic retinopathy involve blockade of diabetes-induced activation of NADPH oxidase and STAT3. METHODS The hypothesis was tested by experiments in which rats with streptozotocin (STZ)-induced diabetes and retinal endothelial cells maintained in high-glucose medium were treated with simvastatin. Blood-retinal barrier (BRB) function was assayed by determining extravasation of albumin. Oxidative stress was assayed by measuring lipid peroxidation, protein nitration of tyrosine, dihydroethidine oxidation, and chemiluminescence. Immunoprobe techniques were used to determine the levels of NADPH oxidase subunit expression and STAT3 activation. RESULTS These studies showed that simvastatin blocks diabetes or high-glucose-induced increases in VEGF and ICAM-1 and preserves the BRB by a process involving blockade of diabetes/high-glucose-induced activation of STAT3 and NADPH oxidase. Statin treatment also prevents diabetes-induced increases in expression of the NADPH oxidase catalytic and subunit NOX2. CONCLUSIONS These results suggest that simvastatin protects against the early signs of diabetic retinopathy by preventing NADPH oxidase-mediated activation of STAT3.

[1]  R. Caldwell,et al.  Simvastatin Improves Diabetes-Induced Coronary Endothelial Dysfunction , 2006, Journal of Pharmacology and Experimental Therapeutics.

[2]  M. Bartoli,et al.  Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. , 2005, Free radical biology & medicine.

[3]  S. Feman,et al.  Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin-induced diabetic rats. , 2005, Diabetes.

[4]  G. Semenza,et al.  Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways , 2005, Oncogene.

[5]  D. Bell,et al.  Statin neuropathy masquerading as diabetic autoimmune polyneuropathy. , 2005, Diabetes Care.

[6]  A. Smaldone,et al.  Characteristics of California children with single versus multiple diabetic ketoacidosis hospitalizations (1998-2000). , 2005, Diabetes care.

[7]  M. Bartoli,et al.  Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. , 2005, The American journal of pathology.

[8]  S. Grundy.  The issue of statin safety: where do we stand? , 2005, Circulation.

[9]  M. Bartoli,et al.  Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. , 2005, Current drug targets.

[10]  R. Alexander,et al.  Role of gp91phox (Nox2)-Containing NAD(P)H Oxidase in Angiogenesis in Response to Hindlimb Ischemia , 2005, Circulation.

[11]  Y. Khalifa,et al.  Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. , 2005, The American journal of pathology.

[12]  F. Kummerow,et al.  Atorvastatin reduces the plasma lipids and oxidative stress but did not reverse the inhibition of prostacyclin generation by aortas in streptozotocin diabetic rats. , 2005, Prostaglandins & other lipid mediators.

[13]  T. Imaizumi,et al.  Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF , 2005, Cell and Tissue Research.

[14]  R. Alexander,et al.  Reactive oxygen species as mediators of angiogenesis signaling. Role of NAD(P)H oxidase , 2004, Molecular and Cellular Biochemistry.

[15]  A. Ceylan,et al.  Simvastatin treatment restores vasoconstriction and the inhibitory effect of LPC on endothelial relaxation via affecting oxidizing metabolism in diabetic rats. , 2004, Diabetes, nutrition & metabolism.

[16]  A. Tsujikawa,et al.  Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes. , 2004, The American journal of pathology.

[17]  F. Ali-Osman,et al.  Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis , 2004, Oncogene.

[18]  Y. Yamori,et al.  Tea polyphenols regulate nicotinamide adenine dinucleotide phosphate oxidase subunit expression and ameliorate angiotensin II-induced hyperpermeability in endothelial cells. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[19]  M. Bartoli,et al.  VEGF differentially activates STAT3 in microvascular endothelial cells , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  R. Caldwell,et al.  Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. , 2003, The American journal of pathology.

[21]  Chia-Hung Chou,et al.  Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway , 2003, Oncogene.

[22]  J. Sowers.  Effects of statins on the vasculature: Implications for aggressive lipid management in the cardiovascular metabolic syndrome. , 2003, The American journal of cardiology.

[23]  J. Abbruzzese,et al.  Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis , 2003, Oncogene.

[24]  Chad Johnson,et al.  Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. , 2002, Circulation research.

[25]  Hua Yu,et al.  Roles of activated Src and Stat3 signaling in melanoma tumor cell growth , 2002, Oncogene.

[26]  F. Djouad,et al.  Statins, 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors, Are Able to Reduce Superoxide Anion Production by NADPH Oxidase in THP-1-Derived Monocytes , 2002, Journal of cardiovascular pharmacology.

[27]  L. Ellis,et al.  Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis , 2002, Oncogene.

[28]  M. Stevens,et al.  Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats , 2001, Diabetologia.

[29]  D. Harrison,et al.  Electron spin resonance characterization of the NAD(P)H oxidase in vascular smooth muscle cells. , 2001, Free radical biology & medicine.

[30]  U. Laufs,et al.  Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. , 2001, Molecular pharmacology.

[31]  Z. Radisavljevic,et al.  Vascular Endothelial Growth Factor Up-regulates ICAM-1 Expression via the Phosphatidylinositol 3 OH-kinase/AKT/Nitric Oxide Pathway and Modulates Migration of Brain Microvascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[32]  J. Dodd-O,et al.  Effect of the NADPH oxidase inhibitor apocynin on ischemia-reperfusion lung injury. , 2000, American journal of physiology. Heart and circulatory physiology.

[33]  Pavel Kovarik,et al.  Serine phosphorylation of STATs , 2000, Oncogene.

[34]  J. Farmer.  Pleiotropic effects of statins , 2000, Current atherosclerosis reports.

[35]  Y. Fujio,et al.  Signal Transducer and Activator of Transcription 3 Is Required for Glycoprotein 130-mediated Induction of Vascular Endothelial Growth Factor in Cardiac Myocytes* , 2000, The Journal of Biological Chemistry.

[36]  J. Tarbell,et al.  Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. , 1998, Diabetes.

[37]  B. Davidson,et al.  Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. , 1998, Circulation research.

[38]  R. Caldwell,et al.  Angiostatic role or astrocytes: Suppression of vascular endothelial cell growth by TGF‐β and other inhibitory factor(s) , 1995, Glia.

[39]  N. Ferrara,et al.  Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. , 1989, Biochemical and biophysical research communications.

[40]  K. Yagi,et al.  Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. , 1979, Analytical biochemistry.

[41]  S. Yamagishi,et al.  Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy. , 2006, Medical hypotheses.

[42]  P. Neumann,et al.  NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-α , 2004 .

[43]  P. Neumann,et al.  NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-alpha. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[44]  T. Gardner,et al.  Molecular mechanisms of vascular permeability in diabetic retinopathy. , 1999, Seminars in ophthalmology.